Abstract
Ruxolitinib cream is a Janus kinase inhibitor under investigation for vitiligo treatment. Vitiligo lesion location affects repigmentation likelihood. Meta-analyses of phototherapy and topical calcineurin inhibitors for vitiligo demonstrated no evidence of marked (≥75%) repigmentation of hands/feet. This 52-week, randomized, double-blind, phase 2 study (NCT03099304) enrolled adult patients with vitiligo that included depigmentation ≥0.5% of body surface area (BSA) on the face and ≥3% of, BSA on nonfacial areas.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
